John E Call, MD
Dermatology · Livermore
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 5 carriers
- Offices
- 2
- Since medical school
- 10 years
- Graduated 2016
Offices
2 locations · Golden State Dermatology Associates, Inc. · 118 clinicians in this group
Hospitals listed: Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
18 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Call’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A169621 · Current
Licensed to practise in California · since 2020 · expires 2028-08-31 · Texas A & M University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$1,153,140
Medicare paid this office $1,153,140 for 1,253 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, tildrakizumab, 1 mg | 19 | $558,315 | None |
| Short return visit (20+ min) | 998 | $160,922 | $84 |
| Destruction of skin growth, 1-14 growths | 388 | $57,509 | $116 |
| Biopsy of related skin growth, first growth | 472 | $55,226 | $92 |
| Destruction of precancer skin growth, 1 growth | 618 | $49,954 | $52 |
See all 33 services
| Injection, tildrakizumab, 1 mg | 19 | $558,315 | None |
| Short return visit (20+ min) | 998 | $160,922 | $84 |
| Destruction of skin growth, 1-14 growths | 388 | $57,509 | $116 |
| Biopsy of related skin growth, first growth | 472 | $55,226 | $92 |
| Destruction of precancer skin growth, 1 growth | 618 | $49,954 | $52 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 108 | $38,090 | $323 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 96 | $22,047 | $176 |
| Return visit (30+ min) | 108 | $21,259 | $122 |
| Destruction of precancer skin growth, 2-14 growths | 436 | $20,966 | $7 |
| Short return visit | 249 | $18,225 | $57 |
| New patient visit (30+ min) | 183 | $17,622 | $96 |
| Biopsy of related skin growth, each additional growth | 131 | $12,102 | $55 |
| Destruction of precancer skin growth, 15 or more growths | 52 | $11,501 | $177 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 77 | $10,535 | $132 |
| Simple or single drainage of skin abscess | 51 | $6,978 | $132 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 32 | $5,554 | $154 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 17 | $4,801 | $282 |
| Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 19 | $4,214 | $201 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 28 | $3,939 | $116 |
| Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | 18 | $3,902 | $195 |
| Injection of drug or substance under skin or into muscle | 66 | $3,344 | $15 |
| Punch biopsy, first skin growth | 21 | $2,931 | $122 |
| Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 13 | $2,780 | $199 |
| Administration of chemotherapy into growth, 1-7 | 22 | $2,774 | $73 |
| Biopsy of ear | 29 | $2,358 | $76 |
| Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 16 | $2,338 | $146 |
| New patient visit (45+ min) | 15 | $1,803 | $120 |
| Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 11 | $1,732 | $144 |
| Destruction of skin growth, 15 or more growths | 11 | $1,638 | $149 |
| Injection into skin growth, 1-7 growths | 26 | $1,473 | $49 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 23 | $291 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 62 | $114 | None |
| Injection, fluorouracil, 500 mg | 22 | $88 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 167 | More than 96% of doctors who do this |
| Removal of nail tissue | 1-10 | None |
| Removal of skin lesions | 2824 | More than 99% of doctors who do this |
| Removal or shaving of skin growth | 95 | More than 84% of doctors who do this |
| Skin biopsy | 893 | More than 98% of doctors who do this |
Procedures year by year
| Procedure | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 147 | 1,338 | 2,727 | 2,928 | 2,849 |
| Destruction of precancer skin growth, 1 growth | 63 | 422 | 775 | 887 | 955 |
| Biopsy of related skin growth, first growth | 34 | 369 | 487 | 526 | 603 |
| Destruction of skin growth, 1-14 growths | 26 | 200 | 350 | 478 | 497 |
| Biopsy of related skin growth, each additional growth | – | 148 | 158 | 163 | 222 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 24 | 138 | 147 | 102 | 118 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,253 Original Medicare patients in 2024. Average age 75 · Under 65 2% · 85 and older 12% · Women 45% · Also on Medicaid 4% · Health risk score 0.92. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Coronary heart disease 20% · Chronic kidney disease 19% · Diabetes 17% · Cancer 17% · Atrial fibrillation 17% · Depression 11% · Heart failure 9% · COPD 8% · Dementia 5% · Stroke 5%.
The office billed $2,488,569, Medicare allowed $1,481,084 and paid $1,153,140; for 14,916 services of 86 kinds; $560,575 of it was for drugs given in the office and $592,565 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,253 | 14,916 | 75 | 0.92 | $2,488,569 | $1,153,140 |
| 2023 | 1,329 | 15,233 | 76 | 0.95 | $2,479,745 | $1,159,473 |
| 2022 | 1,123 | 11,128 | 76 | 0.95 | $1,805,580 | $763,468 |
| 2021 | 867 | 4,893 | 76 | 0.97 | $974,858 | $345,144 |
| 2020 | 184 | 543 | 74 | 0.96 | $104,628 | $35,962 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 35 services
| Injection, tildrakizumab, 1 mg | 26 | $649,830 | None |
| Short return visit (20+ min) | 1,069 | $146,427 | $77 |
| Destruction of skin growth, 1-14 growths | 399 | $51,760 | $108 |
| Biopsy of related skin growth, first growth | 415 | $45,918 | $87 |
| Destruction of precancer skin growth, 1 growth | 596 | $41,727 | $47 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 94 | $30,662 | $301 |
| Destruction of precancer skin growth, 2-14 growths | 439 | $19,909 | $7 |
| New patient visit (30+ min) | 204 | $18,256 | $89 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 84 | $16,767 | $164 |
| Return visit (30+ min) | 81 | $14,208 | $113 |
| Short return visit | 196 | $13,737 | $53 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 77 | $10,309 | $124 |
| Biopsy of related skin growth, each additional growth | 115 | $8,300 | $51 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 27 | $7,078 | $262 |
| Destruction of precancer skin growth, 15 or more growths | 34 | $6,301 | $166 |
| Intermediate repair of wound of neck, hands, feet, or genitals, 2.5 cm or less | 15 | $3,690 | $246 |
| Injection of drug or substance under skin or into muscle | 91 | $3,616 | $13 |
| Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 19 | $3,534 | $186 |
| Simple or single drainage of skin abscess | 28 | $3,415 | $118 |
| Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | 13 | $3,377 | $260 |
| Punch biopsy, first skin growth | 21 | $2,862 | $124 |
| Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 14 | $2,806 | $200 |
| Administration of chemotherapy into growth, 1-7 | 11 | $2,687 | $77 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 24 | $2,647 | $95 |
| Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 19 | $2,557 | $135 |
| Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | 13 | $2,447 | $188 |
| Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 13 | $2,238 | $160 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 13 | $1,819 | $140 |
| Injection into skin growth, 1-7 growths | 36 | $1,708 | $42 |
| Biopsy of ear | 20 | $1,531 | $73 |
| New patient visit (45+ min) | 11 | $1,464 | $133 |
| Removal of cancer skin growth of body, arms, or legs, 0.6-1.0 cm | 12 | $1,393 | $116 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 45 | $640 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 90 | $161 | None |
| Injection, fluorouracil, 500 mg | 11 | $78 | None |
2022: 29 services
| Injection, tildrakizumab, 1 mg | 16 | $281,771 | None |
| Short return visit (20+ min) | 868 | $121,994 | $78 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 127 | $43,227 | $294 |
| Biopsy of related skin growth, first growth | 412 | $42,761 | $88 |
| Destruction of skin growth, 1-14 growths | 286 | $36,501 | $104 |
| Destruction of precancer skin growth, 1 growth | 542 | $35,611 | $46 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 17 | $21,621 | $156 |
| Destruction of precancer skin growth, 2-14 growths | 409 | $18,675 | $7 |
| New patient visit (30+ min) | 196 | $16,880 | $86 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 101 | $13,805 | $122 |
| Return visit (30+ min) | 86 | $11,585 | $107 |
| Destruction of precancer skin growth, 15 or more growths | 55 | $10,186 | $157 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 59 | $9,872 | $154 |
| Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | 30 | $9,195 | $307 |
| Short return visit | 141 | $9,019 | $51 |
| Biopsy of related skin growth, each additional growth | 113 | $8,133 | $51 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 21 | $5,377 | $244 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 36 | $5,316 | $136 |
| Administration of chemotherapy into growth, 1-7 | 14 | $4,601 | $82 |
| Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 31 | $3,854 | $124 |
| Injection of drug or substance under skin or into muscle | 78 | $3,512 | $14 |
| Punch biopsy, first skin growth | 23 | $3,030 | $126 |
| Simple or single drainage of skin abscess | 24 | $2,824 | $118 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 17 | $2,739 | $114 |
| Biopsy of ear | 33 | $2,664 | $74 |
| Injection into skin growth, 1-7 growths | 28 | $1,417 | $40 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 41 | $567 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 78 | $138 | None |
| Injection, fluorouracil, 500 mg | 14 | $93 | None |
2021: 28 services
| Short return visit (20+ min) | 565 | $67,762 | $80 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 120 | $42,243 | $306 |
| Biopsy of related skin growth, first growth | 310 | $32,685 | $89 |
| Destruction of skin growth, 1-14 growths | 161 | $21,100 | $105 |
| Destruction of precancer skin growth, 1 growth | 329 | $19,895 | $47 |
| Return visit (30+ min) | 90 | $14,046 | $110 |
| New patient visit (30+ min) | 155 | $13,528 | $87 |
| Destruction of precancer skin growth, 15 or more growths | 67 | $13,187 | $163 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 15 | $12,718 | $165 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 77 | $10,278 | $125 |
| Destruction of precancer skin growth, 2-14 growths | 234 | $8,605 | $6 |
| Biopsy of related skin growth, each additional growth | 87 | $7,623 | $52 |
| Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | 25 | $7,339 | $294 |
| Short return visit | 115 | $5,996 | $48 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 17 | $4,570 | $269 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 31 | $4,322 | $139 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 19 | $3,757 | $163 |
| Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 22 | $2,932 | $133 |
| New patient visit (45+ min) | 17 | $2,312 | $136 |
| Punch biopsy, first skin growth | 15 | $1,951 | $130 |
| Removal of cancer skin growth of body, arms, or legs, 3.1-4.0 cm | 11 | $1,508 | $137 |
| Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | 15 | $1,392 | $87 |
| Biopsy of ear | 19 | $1,258 | $63 |
| Injection into skin growth, 1-7 growths | 20 | $930 | $42 |
| New patient visit (15+ min) | 18 | $847 | $47 |
| Injection of drug or substance under skin or into muscle | 34 | $784 | $13 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 19 | $197 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 46 | $82 | None |
2020: 10 services
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 23 | $7,142 | $298 |
| Short return visit (20+ min) | 74 | $5,695 | $65 |
| Destruction of precancer skin growth, 1 growth | 56 | $3,163 | $50 |
| Biopsy of related skin growth, first growth | 34 | $2,591 | $76 |
| Destruction of skin growth, 1-14 growths | 26 | $2,372 | $91 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 15 | $2,092 | $123 |
| New patient visit (15+ min) | 28 | $1,512 | $54 |
| Short return visit | 22 | $1,017 | $42 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $857 | $6 |
| New patient visit (30+ min) | 14 | $852 | $61 |
Drugs they prescribed that Part D paid
$751,471
Pharmacies billed $751,471 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,433) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,324 generic and 109 brand-name prescriptions · $751,471 in drug cost · 44 antibiotic prescriptions to 38 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cosentyx Sensoready (2 Pens) | 13 | $97,106 | $7,470 |
| Otezla | 13 | $62,786 | $4,830 |
| Dupixent | 16 | $57,237 | $3,577 |
| Tacrolimus | 65 | $7,692 | $118 |
| Fluorouracil | 69 | $5,192 | $75 |
See all 31 drugs
| Cosentyx Sensoready (2 Pens) | 13 | $97,106 | $7,470 |
| Otezla | 13 | $62,786 | $4,830 |
| Dupixent | 16 | $57,237 | $3,577 |
| Tacrolimus | 65 | $7,692 | $118 |
| Fluorouracil | 69 | $5,192 | $75 |
| Clobetasol Propionate | 86 | $4,116 | $48 |
| Ketoconazole | 159 | $2,838 | $18 |
| Betamethasone Diprop Augmented | 120 | $2,809 | $23 |
| Metronidazole | 39 | $1,898 | $49 |
| Triamcinolone Acetonide | 152 | $1,854 | $12 |
| Calcipotriene | 13 | $1,504 | $116 |
| Fluocinonide | 29 | $979 | $34 |
| Desonide | 21 | $890 | $42 |
| Alclometasone Dipropionate | 35 | $886 | $25 |
| Clindamycin Phosphate | 31 | $739 | $24 |
| Fluocinolone Acetonide | 11 | $711 | $65 |
| Doxycycline Hyclate | 40 | $661 | $17 |
| Valacyclovir | 17 | $579 | $34 |
| Betamethasone Dipropionate | 16 | $564 | $35 |
| Minoxidil | 33 | $430 | $13 |
| Levocetirizine Dihydrochloride | 22 | $426 | $19 |
| Mometasone Furoate | 21 | $377 | $18 |
| Ciclopirox | 13 | $369 | $28 |
| Hydrocortisone | 76 | $338 | $4 |
| Terbinafine | 13 | $287 | $22 |
| Mupirocin | 40 | $273 | $7 |
| Nystatin | 23 | $201 | $9 |
| Gabapentin | 23 | $158 | $7 |
| Prednisone | 28 | $120 | $4 |
| Hydroxyzine | 21 | $102 | $5 |
| Clotrimazole | 13 | $79 | $6 |
Year by year
| 2024 | 1,433 | 549 | 0% (0) | 8% | $751,471 |
| 2023 | 1,259 | 575 | 0% (0) | 8% | $285,345 |
| 2022 | 897 | 469 | 0% (0) | 6% | $166,394 |
| 2021 | 707 | 353 | 0% (0) | 5% | $55,604 |
| 2020 | 593 | 270 | 0% (0) | 22% | $693,350 |
| 2019 | 460 | 216 | 0% (0) | 15% | $343,309 |
| 2018 | 263 | 124 | 0% (0) | 21% | $130,661 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Cosentyx Sensoready (2 Pens) | 11 | $76,793 | $6,981 |
| Otezla | 11 | $54,083 | $4,917 |
| Tacrolimus | 33 | $5,171 | $157 |
| Fluorouracil | 54 | $4,644 | $86 |
| Ketoconazole | 162 | $3,601 | $22 |
| Clobetasol Propionate | 71 | $3,498 | $49 |
| Betamethasone Diprop Augmented | 83 | $3,406 | $41 |
| Metronidazole | 35 | $2,672 | $76 |
| Triamcinolone Acetonide | 178 | $2,643 | $15 |
| Fluocinonide | 40 | $2,203 | $55 |
| Desonide | 23 | $1,732 | $75 |
| Alclometasone Dipropionate | 36 | $1,346 | $37 |
| Valacyclovir | 30 | $1,145 | $38 |
| Clindamycin Phosphate | 23 | $1,070 | $47 |
| Betamethasone Dipropionate | 17 | $883 | $52 |
| Doxycycline Hyclate | 40 | $793 | $20 |
| Hydrocortisone | 64 | $474 | $7 |
| Minoxidil | 23 | $412 | $18 |
| Mometasone Furoate | 15 | $405 | $27 |
| Levocetirizine Dihydrochloride | 11 | $303 | $28 |
| Mupirocin | 33 | $282 | $9 |
| Prednisone | 30 | $202 | $7 |
| Nystatin | 16 | $170 | $11 |
| Gabapentin | 24 | $164 | $7 |
2022: 18 drugs
| Tacrolimus | 39 | $8,944 | $229 |
| Fluorouracil | 33 | $3,309 | $100 |
| Ketoconazole | 111 | $3,234 | $29 |
| Alclometasone Dipropionate | 62 | $3,167 | $51 |
| Betamethasone Diprop Augmented | 46 | $2,666 | $58 |
| Clobetasol Propionate | 47 | $2,559 | $54 |
| Triamcinolone Acetonide | 125 | $1,785 | $14 |
| Fluocinonide | 28 | $1,360 | $49 |
| Clindamycin Phosphate | 27 | $1,323 | $49 |
| Doxycycline Hyclate | 41 | $1,147 | $28 |
| Metronidazole | 12 | $1,130 | $94 |
| Mometasone Furoate | 31 | $962 | $31 |
| Valacyclovir | 18 | $922 | $51 |
| Betamethasone Dipropionate | 15 | $580 | $39 |
| Mupirocin | 32 | $357 | $11 |
| Hydrocortisone | 37 | $267 | $7 |
| Minoxidil | 13 | $189 | $15 |
| Prednisone | 13 | $76 | $6 |
2021: 15 drugs
| Tacrolimus | 31 | $8,817 | $284 |
| Betamethasone Diprop Augmented | 68 | $4,342 | $64 |
| Fluorouracil | 25 | $2,687 | $107 |
| Clobetasol Propionate | 28 | $2,293 | $82 |
| Ketoconazole | 91 | $2,134 | $23 |
| Triamcinolone Acetonide | 140 | $1,628 | $12 |
| Alclometasone Dipropionate | 32 | $1,552 | $49 |
| Fluocinonide | 28 | $1,392 | $50 |
| Clindamycin Phosphate | 15 | $690 | $46 |
| Valacyclovir | 11 | $563 | $51 |
| Doxycycline Hyclate | 23 | $402 | $17 |
| Mometasone Furoate | 12 | $326 | $27 |
| Mupirocin | 27 | $215 | $8 |
| Prednisone | 28 | $198 | $7 |
| Hydrocortisone | 18 | $153 | $8 |
2020: 17 drugs
| Stelara | 20 | $309,349 | $15,467 |
| Cosentyx Pen (2 Pens) | 17 | $116,209 | $6,836 |
| Dupixent | 22 | $71,989 | $3,272 |
| Tacrolimus | 29 | $13,547 | $467 |
| Betamethasone Diprop Augmented | 55 | $4,858 | $88 |
| Fluorouracil | 18 | $2,217 | $123 |
| Doxycycline Hyclate | 19 | $2,191 | $115 |
| Betamethasone Dipropionate | 20 | $1,914 | $96 |
| Triamcinolone Acetonide | 95 | $1,656 | $17 |
| Mycophenolate Mofetil | 14 | $1,610 | $115 |
| Fluocinonide | 22 | $1,544 | $70 |
| Ketoconazole | 33 | $960 | $29 |
| Clobetasol Propionate | 17 | $740 | $44 |
| Methotrexate | 12 | $340 | $28 |
| Clindamycin Phosphate | 11 | $214 | $19 |
| Prednisone | 19 | $167 | $9 |
| Mupirocin | 14 | $122 | $9 |
2019: 12 drugs
| Humira | 11 | $64,160 | $5,833 |
| Tacrolimus | 15 | $5,950 | $397 |
| Betamethasone Diprop Augmented | 50 | $4,856 | $97 |
| Fluocinonide | 22 | $1,693 | $77 |
| Ketoconazole | 35 | $1,530 | $44 |
| Doxycycline Hyclate | 17 | $1,484 | $87 |
| Triamcinolone Acetonide | 67 | $1,305 | $19 |
| Fluorouracil | 12 | $1,243 | $104 |
| Mycophenolate Mofetil | 12 | $986 | $82 |
| Methotrexate | 23 | $755 | $33 |
| Prednisone | 20 | $194 | $10 |
| Mupirocin | 15 | $163 | $11 |
2018: 6 drugs
| Tacrolimus | 11 | $4,688 | $426 |
| Betamethasone Diprop Augmented | 22 | $2,012 | $91 |
| Ketoconazole | 26 | $1,433 | $55 |
| Doxycycline Hyclate | 15 | $1,294 | $86 |
| Triamcinolone Acetonide | 50 | $825 | $17 |
| Prednisone | 14 | $100 | $7 |
Money from drug and device companies
$23,298 in 2025
| 2025 | 22 | 182 | $16,758 | $23,298 |
| 2024 | 21 | 218 | $18,948 | $23,807 |
| 2023 | 18 | 180 | $12,437 | $16,448 |
| 2022 | 15 | 105 | None | $2,653 |
| 2021 | 10 | 49 | None | $971 |
| 2020 | 2 | 2 | None | $83 |
| 2019 | 2 | 2 | None | $274 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Dupixent | $14,388 | 20 payments
|
| Genzyme | Dupixent | $5,712 | 7 payments
|
| Incyte | Opzelura | $506 | 27 payments
|
| Lilly USA | Taltz | $431 | 18 payments
|
| Arcutis Biotherapeutics | Zoryve | $382 | 19 payments
|
| Janssen Biotech | Tremfya | $367 | 12 payments
|
See all 182 published payments
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-12-22 | Jublia | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-12-19 | Dupixent | $30 |
| Incyte | Meals · 2025-12-10 | Opzelura | $24 |
| Novartis Pharmaceuticals | Meals · 2025-12-09 | Cosentyx | $16 |
| Arcutis Biotherapeutics | Meals · 2025-12-09 | Zoryve | $10 |
| Novartis Pharmaceuticals | Meals · 2025-12-08 | Cosentyx | $15 |
| Botanix SB | Meals · 2025-12-08 | Sofdra | $25 |
| Journey Medical | Meals · 2025-12-08 | None | $35 |
| Incyte | Meals · 2025-12-05 | Opzelura | $29 |
| Pfizer | Meals · 2025-12-04 | Cibinqo | $21 |
| Novartis Pharmaceuticals | Meals · 2025-12-03 | Rhapsido | $32 |
| Almirall | Meals · 2025-12-03 | Klisyri | $28 |
| Abbvie | Meals · 2025-12-02 | Skyrizi | $13 |
| Pfizer | Meals · 2025-12-02 | Cibinqo | $27 |
| Abbvie | Meals · 2025-11-24 | Skyrizi | $16 |
| Incyte | Meals · 2025-11-24 | Opzelura | $29 |
| Janssen Biotech | Meals · 2025-11-17 | Tremfya | $22 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-11-17 | Jublia | $15 |
| Ucb | Meals · 2025-11-17 | Bimzelx | $17 |
| Ucb | Meals · 2025-11-13 | Bimzelx | $13 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Rhapsido | $31 |
| Abbvie | Meals · 2025-11-10 | Skyrizi | $10 |
| Arcutis Biotherapeutics | Meals · 2025-11-10 | Zoryve | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-11-07 | Dupixent | $14 |
| Incyte | Meals · 2025-11-06 | Opzelura | $18 |
| Novartis Pharmaceuticals | Meals · 2025-11-05 | Rhapsido | $18 |
| Pfizer | Meals · 2025-11-05 | Cibinqo | $24 |
| Incyte | Meals · 2025-11-03 | Opzelura | $12 |
| Galderma Laboratories L.P. | Meals · 2025-11-03 | Nemluvio | $18 |
| Abbvie | Meals · 2025-10-31 | Skyrizi | $25 |
| Ucb | Meals · 2025-10-31 | Bimzelx | $13 |
| Sun Pharmaceutical Industries | Meals · 2025-10-21 | Ilumya | $38 |
| Lilly USA | Meals · 2025-10-20 | Taltz | $23 |
| Ucb | Meals · 2025-10-20 | Bimzelx | $16 |
| Incyte | Meals · 2025-10-20 | Opzelura | $18 |
| Abbvie | Meals · 2025-10-15 | Skyrizi | $12 |
| Arcutis Biotherapeutics | Meals · 2025-10-15 | Zoryve | $18 |
| Regeneron Healthcare Solutions | Meals · 2025-10-07 | Dupixent | $28 |
| Janssen Biotech | Meals · 2025-10-03 | Tremfya | $30 |
| Ucb | Meals · 2025-10-03 | Bimzelx | $15 |
| Incyte | Meals · 2025-10-03 | Opzelura | $24 |
| Arcutis Biotherapeutics | Meals · 2025-10-03 | Zoryve | $10 |
| Incyte | Meals · 2025-10-02 | Opzelura | $11 |
| Regeneron Healthcare Solutions | Meals · 2025-10-01 | Dupixent | $16 |
| Abbvie | Meals · 2025-09-30 | Rinvoq | $26 |
| Janssen Biotech | Meals · 2025-09-29 | Tremfya | $22 |
| Abbvie | Meals · 2025-09-28 | Skyrizi | $27 |
| Incyte | Meals · 2025-09-25 | Opzelura | $30 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-09-22 | Jublia | $23 |
| Sun Pharmaceutical Industries | Meals · 2025-09-18 | Ilumya | $19 |
| Pfizer | Meals · 2025-09-09 | Cibinqo | $28 |
| Sun Pharmaceutical Industries | Meals · 2025-09-09 | Ilumya | $41 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $25 |
| Abbvie | Meals · 2025-09-03 | Skyrizi | $19 |
| Organon | Meals · 2025-09-03 | None | $35 |
| Arcutis Biotherapeutics | Meals · 2025-09-03 | Zoryve | $12 |
| Lilly USA | Meals · 2025-08-29 | Taltz | $30 |
| Cipher Pharmaceuticals US | Meals · 2025-08-29 | Natroba | $15 |
| Arcutis Biotherapeutics | Meals · 2025-08-29 | Zoryve | $22 |
| LEO Pharma | Meals · 2025-08-27 | Anzupgo | $18 |
| Arcutis Biotherapeutics | Meals · 2025-08-26 | Zoryve | $9 |
| Abbvie | Meals · 2025-08-25 | Skyrizi | $12 |
| Ucb | Meals · 2025-08-25 | Bimzelx | $14 |
| Abbvie | Meals · 2025-08-22 | Skyrizi | $14 |
| Arcutis Biotherapeutics | Meals · 2025-08-21 | Zoryve | $22 |
| Genzyme | Meals · 2025-08-20 | Dupixent | $32 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-15 | Dupixent | $4,522 |
| Regeneron Healthcare Solutions | Travel · 2025-08-14 | Dupixent | $786 |
| Lilly USA | Meals · 2025-08-11 | Taltz | $31 |
| Pfizer | Meals · 2025-08-04 | Cibinqo | $18 |
| Regeneron Healthcare Solutions | Education · 2025-07-28 | Dupixent | $99 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-25 | Dupixent | $931 |
| Arcutis Biotherapeutics | Meals · 2025-07-25 | Zoryve | $24 |
| Ucb | Meals · 2025-07-21 | Bimzelx | $18 |
| Incyte | Meals · 2025-07-19 | Opzelura | $28 |
| Hill Dermaceuticals | Meals · 2025-07-16 | Tolak | $24 |
| Incyte | Meals · 2025-07-16 | Opzelura | $14 |
| Arcutis Biotherapeutics | Meals · 2025-07-15 | Zoryve | $25 |
| Ucb | Meals · 2025-07-14 | Bimzelx | $17 |
| Incyte | Meals · 2025-07-08 | Opzelura | $13 |
| Lilly USA | Meals · 2025-07-07 | Taltz | $31 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-06-30 | Jublia | $22 |
| Abbvie | Meals · 2025-06-28 | Skyrizi | $6 |
| Incyte | Meals · 2025-06-28 | Opzelura | $27 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-27 | Dupixent | $4,522 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-27 | Dupixent | $2,261 |
| Incyte | Meals · 2025-06-27 | Opzelura | $22 |
| Regeneron Healthcare Solutions | Travel · 2025-06-26 | Dupixent | $750 |
| Galderma Laboratories L.P. | Meals · 2025-06-26 | Nemluvio | $17 |
| Ucb | Meals · 2025-06-25 | Bimzelx | $14 |
| Lilly USA | Meals · 2025-06-23 | Taltz | $30 |
| Pfizer | Meals · 2025-06-23 | Cibinqo | $5 |
| Janssen Biotech | Meals · 2025-06-18 | Tremfya | $33 |
| Incyte | Meals · 2025-06-13 | Opzelura | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-12 | Sotyktu | $21 |
| Incyte | Meals · 2025-06-10 | Opzelura | $12 |
| Arcutis Biotherapeutics | Meals · 2025-06-10 | Zoryve | $22 |
| Lilly USA | Meals · 2025-06-06 | Taltz | $13 |
| Abbvie | Meals · 2025-06-04 | Skyrizi | $11 |
| LEO Pharma | Meals · 2025-06-03 | Adbry | $25 |
| Ucb | Meals · 2025-06-02 | Bimzelx | $13 |
| Lilly USA | Meals · 2025-05-30 | Taltz | $33 |
| Incyte | Meals · 2025-05-27 | Opzelura | $11 |
| Arcutis Biotherapeutics | Meals · 2025-05-23 | Zoryve | $24 |
| Janssen Biotech | Meals · 2025-05-21 | Tremfya | $23 |
| Abbvie | Meals · 2025-05-21 | Skyrizi | $8 |
| Regeneron Healthcare Solutions | Meals · 2025-05-20 | Dupixent | $15 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-20 | Spevigo | $28 |
| Incyte | Meals · 2025-05-19 | Opzelura | $20 |
| Ucb | Meals · 2025-05-18 | Bimzelx | $35 |
| Janssen Biotech | Education · 2025-05-12 | Tremfya | $100 |
| Abbvie | Meals · 2025-05-07 | Skyrizi | $8 |
| Regeneron Healthcare Solutions | Meals · 2025-05-06 | Dupixent | $12 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-05-06 | Jublia | $25 |
| Janssen Biotech | Meals · 2025-05-05 | Tremfya | $18 |
| Lilly USA | Meals · 2025-05-05 | Taltz | $24 |
| Lilly USA | Meals · 2025-05-05 | Taltz | $5 |
| Arcutis Biotherapeutics | Meals · 2025-05-02 | Zoryve | $24 |
| Lilly USA | Meals · 2025-04-30 | Taltz | $16 |
| Lilly USA | Meals · 2025-04-30 | Taltz | $6 |
| Abbvie | Meals · 2025-04-30 | Skyrizi | $13 |
| Incyte | Meals · 2025-04-29 | Opzelura | $16 |
| Ucb | Meals · 2025-04-28 | Bimzelx | $16 |
| Incyte | Meals · 2025-04-25 | Opzelura | $11 |
| Regeneron Healthcare Solutions | Meals · 2025-04-22 | Dupixent | $30 |
| Janssen Biotech | Meals · 2025-04-21 | Tremfya | $19 |
| Arcutis Biotherapeutics | Meals · 2025-04-21 | Zoryve | $17 |
| Arcutis Biotherapeutics | Meals · 2025-04-17 | Zoryve | $26 |
| Abbvie | Meals · 2025-04-16 | Rinvoq | $29 |
| Lilly USA | Meals · 2025-04-14 | Taltz | $26 |
| Abbvie | Meals · 2025-04-14 | Skyrizi | $14 |
| Incyte | Meals · 2025-04-10 | Opzelura | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-04-09 | Dupixent | $31 |
| Genzyme | Meals · 2025-04-07 | Dupixent | $16 |
| Lilly USA | Meals · 2025-04-04 | Taltz | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-26 | Sotyktu | $31 |
| Incyte | Meals · 2025-03-26 | Opzelura | $14 |
| Pfizer | Meals · 2025-03-24 | Cibinqo | $14 |
| Genzyme | Meals · 2025-03-21 | Dupixent | $150 |
| Genzyme | Paid to speak or teach · 2025-03-21 | Dupixent | $4,522 |
| Genzyme | Travel · 2025-03-21 | Dupixent | $929 |
| Incyte | Meals · 2025-03-20 | Opzelura | $10 |
| Incyte | Meals · 2025-03-20 | Opzelura | $8 |
| Botanix SB | Meals · 2025-03-20 | Sofdra | $22 |
| Incyte | Meals · 2025-03-07 | Opzelura | $26 |
| Galderma Laboratories L.P. | Meals · 2025-03-06 | Nemluvio | $19 |
| Abbvie | Meals · 2025-03-04 | Skyrizi | $22 |
| Janssen Biotech | Meals · 2025-03-03 | Tremfya | $19 |
| Ucb | Meals · 2025-03-03 | Bimzelx | $11 |
| Arcutis Biotherapeutics | Meals · 2025-02-28 | Zoryve | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-02-25 | Dupixent | $14 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-02-25 | Siliq | $18 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-02-25 | Siliq | $20 |
| Lilly USA | Meals · 2025-02-24 | Taltz | $25 |
| Abbvie | Meals · 2025-02-20 | Skyrizi | $17 |
| Incyte | Meals · 2025-02-20 | Opzelura | $29 |
| Abbvie | Education · 2025-02-19 | Skyrizi | $10 |
| Arcutis Biotherapeutics | Meals · 2025-02-14 | Zoryve | $19 |
| Lilly USA | Meals · 2025-02-12 | Taltz | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-02-12 | Dupixent | $37 |
| Galderma Laboratories L.P. | Meals · 2025-02-11 | Nemluvio | $19 |
| Ucb | Meals · 2025-02-10 | Bimzelx | $16 |
| Pfizer | Meals · 2025-02-10 | Cibinqo | $13 |
| Janssen Biotech | Meals · 2025-02-05 | Tremfya | $21 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Dupixent | $62 |
| Regeneron Healthcare Solutions | Travel · 2025-02-04 | Dupixent | $200 |
| Genzyme | Meals · 2025-02-04 | Dupixent | $25 |
| Genzyme | Meals · 2025-02-03 | Dupixent | $38 |
| Arcutis Biotherapeutics | Meals · 2025-01-31 | Zoryve | $22 |
| Abbvie | Meals · 2025-01-30 | Skyrizi | $23 |
| Galderma Laboratories L.P. | Meals · 2025-01-29 | Nemluvio | $16 |
| Lilly USA | Meals · 2025-01-27 | Taltz | $32 |
| Abbvie | Meals · 2025-01-25 | Skyrizi | $11 |
| Janssen Biotech | Meals · 2025-01-23 | Tremfya | $35 |
| Lilly USA | Meals · 2025-01-15 | Taltz | $34 |
| Regeneron Healthcare Solutions | Meals · 2025-01-15 | Dupixent | $28 |
| Ucb | Meals · 2025-01-13 | Bimzelx | $13 |
| Pfizer | Meals · 2025-01-13 | Cibinqo | $4 |
| Pfizer | Meals · 2025-01-13 | Cibinqo | $23 |
| Incyte | Meals · 2025-01-10 | Opzelura | $15 |
| Arcutis Biotherapeutics | Meals · 2025-01-10 | Zoryve | $31 |
| Lilly USA | Meals · 2025-01-03 | Taltz | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $23,807
| Genzyme | Dupixent | $10,468 | 18 payments
|
| Regeneron Healthcare Solutions | Dupixent | $9,552 | 15 payments
|
| Abbvie | Skyrizi | $716 | 33 payments
|
| Lilly USA | Taltz | $646 | 32 payments
|
| Incyte | Opzelura | $444 | 22 payments
|
| Arcutis Biotherapeutics | Zoryve | $340 | 23 payments
|
| Novartis Pharmaceuticals | Cosentyx | $219 | 10 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $206 | 10 payments
|
| Janssen Biotech | Tremfya | $194 | 5 payments
|
| Sun Pharmaceutical Industries | Ilumya | $173 | 10 payments
|
| Dermavant Sciences | Vtama | $138 | 5 payments
|
| Ucb | Bimzelx | $135 | 9 payments
|
| Galderma Laboratories L.P. | Aklief | $93 | 5 payments
|
| Amgen | Otezla | $92 | 4 payments
|
| LEO Pharma | Adbry | $75 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $70 | 3 payments
|
| Pfizer | Cibinqo | $67 | 3 payments
|
| Fresenius Kabi USA | Idacio | $64 | 3 payments
|
| Almirall | Klisyri | $54 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $44 | 2 payments
|
| STRATA Skin Sciences | Xtrac | $16 | 1 payment
|
2023: $16,448
| Genzyme | Dupixent | $8,125 | 22 payments
|
| Regeneron Healthcare Solutions | Dupixent | $5,200 | 11 payments
|
| AbbVie | Skyrizi | $502 | 24 payments
|
| Lilly USA | Taltz | $439 | 19 payments
|
| Sun Pharmaceutical Industries | Ilumya | $363 | 17 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $324 | 14 payments
|
| Novartis Pharmaceuticals | Cosentyx | $259 | 13 payments
|
| Janssen Biotech | Tremfya | $212 | 6 payments
|
| Dermavant Sciences | Vtama | $177 | 9 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $155 | 8 payments
|
| Ucb | Cimzia | $148 | 8 payments
|
| Arcutis Biotherapeutics | None | $147 | 11 payments
|
| Incyte | Opzelura | $134 | 6 payments
|
| Amgen | Otezla | $127 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $59 | 2 payments
|
| Helsinn Therapeutics (U.S.) | Valchlor | $34 | 2 payments
|
| Pfizer | Eucrisa | $27 | 1 payment
|
| Journey Medical | None | $16 | 1 payment
|
2022: $2,653
| Abbvie | Skyrizi | $616 | 33 payments
|
| Regeneron Healthcare Solutions | Dupixent | $488 | 10 payments
|
| Journey Medical | None | $257 | 2 payments
|
| Sun Pharmaceutical Industries | Ilumya | $240 | 12 payments
|
| Lilly USA | Taltz | $216 | 9 payments
|
| Genzyme | Dupixent | $191 | 9 payments
|
| Novartis Pharmaceuticals | Cosentyx | $144 | 6 payments
|
| Ucb | Cimzia | $135 | 9 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $90 | 4 payments
|
| Incyte | Opzelura | $74 | 3 payments
|
| Amgen | Otezla | $61 | 2 payments
|
| LEO Pharma | Adbry | $56 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $31 | 2 payments
|
| Janssen Biotech | Remicade | $30 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $26 | 1 payment
|
2021: $971
| AbbVie | Skyrizi | $451 | 22 payments
|
| Sun Pharmaceutical Industries | Ilumya | $210 | 11 payments
|
| Genzyme | Dupixent | $71 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $61 | 3 payments
|
| Allergan | Botox | $56 | 3 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $46 | 2 payments
|
| Amgen | Otezla | $24 | 1 payment
|
| Incyte | Opzelura | $20 | 1 payment
|
| Dermira | Qbrexza | $17 | 1 payment
|
| Galderma Laboratories L.P. | Aklief | $13 | 1 payment
|
2020: $83
| VYNE Pharmaceuticals | Zilxi | $61 | 1 payment
|
| Amgen | Otezla | $22 | 1 payment
|
2019: $274
| AbbVie | Skyrizi | $143 | 1 payment
|
| Celgene | Otezla | $131 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1376997767
- Licence
- CA A169621California A169621: Current · expires 2028-08-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 370 N Wiget Ln Ste 250, Walnut Creek, CA, 94598
- NPI first listed
- 2016-04-21
- NPI last updated
- 2022-07-09
- NPI record certified
- 2022-07-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1074 Murrieta Blvd, Livermore, CA, 94550